New Covid Shots Score Points against Omicron
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
Sanofi
Sanofi Teams up with McLaren Racing
Sanofi has joined forces with McLaren Racing in a move it hopes will accelerate its manufacturing efficiency and performance drive. As the French drugmaker’s CEO Paul Hudson put it, “we want to run our lines with the speed, precision and efficiency of a Formula One racing team.”
EuroAPI’s Euronext Listing Set for May 6
Sanofi has announced it will list its Active Pharmaceutical ingredients company EuroAPI on the Euronext stock exchange in Paris on May 6. Each of the French drugmaker’s shareholders will receive one share in EuroAPI for 23 Sanofi shares in addition to a cash dividend of €3.33 per Sanofi share.
Sanofi in Billion-Dollar Collaboration With IGM
French drugmaker Sanofi has signed an exclusive worldwide collaboration agreement with IGM Biosciences, a clinical-stage biotechnology company. The deal focuses on creating and developing and commercializing engineered IgM antibody antagonists against three oncology targets, along with three immunology/inflammation targets.
Sanofi and Blackstone in €300 Million Collaboration
Sanofi has agreed a €300 million collaboration with private equity investor Blackstone Life Sciences (BXLS) to advance its innovative treatment for multiple myeloma (MM) Sarclisa (isatuximab). The French drugmaker said it will continue to fully manage the clinical program and retain full rights and control of the treatment.
Sanofi and GSK Ready to Apply for Covid Vaccine Approval
After several delays, Sanofi and GlaxoSmithKline are preparing to submit data to regulatory authorities to support approval of their adjuvanted protein vaccine against Covid-19.
Sanofi/GSK Covid Shot Shows Booster Promise
In the VAT 0002 extension trial investigating the safety and immunogenicity of the protein-based recombinant adjuvanted Covid-19 vaccine they are partly developing as a booster, Sanofi and GlaxoSmithKline said the shot delivered a “consistently strong immune response” and was well tolerated, regardless of the vaccine it followed.
Sanofi to Tap Owkin’s AI for Oncology Pipeline
French drugmaker Sanofi is taking an equity stake worth $180 million in and entering a new strategic collaboration with artificial intelligence (AI) and precision medicine specialist Owkin.
Sanofi Invests in Gyroscope, Closes Kadmon Buy
French pharma Sanofi is investing $60 million in Gyroscope Therapeutics, a UK-based clinical-stage gene therapy company focused on eye diseases. Sanofi will initially invest $40 million, with the remaining funds contingent on a future qualifying investment round and the satisfaction of certain closing conditions.
Sanofi Drops mRNA Covid Vaccine Despite Good Results
A year ago unthinkable, the market for mRNA-based Covid-19 vaccines appears to be headed for saturation, even though, or perhaps because, there now seem to be more products on the market than first-world consumers want or need.
Sanofi Completes Translate Bio Acquisition
Sanofi has completed the $3.2 billion acquisition of US biotech Translate Bio after the tender offer for all shares expired as scheduled at midnight US Eastern Daylight Time on Sept. 4. The minimum tender condition and all of the other conditions to the offer were satisfied, the French drugmaker said.
Sanofi to Acquire US Biopharma Kadmon
Sanofi is continuing its drive to diversify and upgrade its pharmaceuticals portfolio through acquisitions. In its latest move, the French drugmaker said it has signed a definitive merger agreement with US biotech Kadmon, a biopharmaceutical company specializing in treatments for unmet needs in transplant medication.
Sanofi to Revise Buyout Plans for Translate Bio
French drugmaker Sanofi may reconsider plans to acquire Translate Bio at the conditions recently announced, the US biotech said in a filing with the US Securities and Exchange Commission (SEC). Translate said Sanofi withdrew and refiled the proposed buyout information recently provided to allow the FTC more time to study it.
Sanofi to Buy mRNA Biotech Translate Bio
French drugmaker Sanofi has signed a definitive agreement to acquire Translate Bio, the clinical-stage mRNA therapeutics company with which it is currently cooperating on a Covid-19 vaccine. Both boards have unanimously approved the proposed all-cash transaction.
EMA Starts Rolling Review of Sanofi-GSK Covid Shot
The human medicines committee of the European Medicines Agency, CHMP, has begun a rolling review of the Covid-19 vaccine developed by Sanofi Pasteur, which following approval is planned to be marketed by drugmaker Sanofi and UK pharma Glaxo SmithKline.
Sanofi Invests in mRNA Center of Excellence
French drugmaker Sanofi plans to invest around €400 million annually in a center of excellence for mRNA vaccines that it hopes will accelerate the development and delivery of the next-generation vaccine portfolio it has built up in collaboration with US biotech Translate Bio. The company said the project will be “fully financed” through resource reallocation.
Sanofi to Sell 16 Consumer Health Drugs to Stada
As part of its drive to reduce the complexity of its Consumer Healthcare (CHC) portfolio, French drugmaker Sanofi has agreed to sell 16 products marketed exclusively in Europe to German generics manufacturer Stada.
Sanofi and GSK to Launch Phase 3 Vaccine Trial
After seeing encouraging results with their adjuvanted recombinant Covid-19 vaccine candidate across all adult age groups in a recently completed Phase 2 trial, Sanofi and GlaxoSmithKline (GSK) are preparing to launch a global Phase 3 randomized double-blind study “in the coming weeks.”
EU Going Ahead With AstraZeneca Lawsuit
The European Commission has confirmed rumors that it has initiated legal action against AstraZeneca for failing to meet contractual obligations for deliveries of Its Covid-19 vaccine. Health commissioner Stella Kyriakides said the action is being taken jointly with all 27 member states.
Sanofi to Build Asian Vaccine Center in Singapore
In partnership with the Singapore Economic Development Board (EDB), French drugmaker Sanofi is planning to invest more than €400 million to create what it said is a “unique vaccine production center that pushes the boundaries of operations through cutting edge manufacturing and digital technologies.” The new site will mainly supply the Asian region and complement existing manufacturing capability in Europe and North America.
Sanofi Plans New Vaccine Plant in Canada
French multinational pharma Sanofi will invest more than €600 million in a new vaccine manufacturing plant at its existing site in Toronto, Canada.
CO2-Neutral Chemical Industry
The European Chemical Industry has set out on an ambitious path to become carbon neutral. Germany, as one of the major chemical manufacturing nations, has committed to achieve this goal by 2050.
Germany Seeks Self Reliance in Vaccine Production
As one glitch after another at Covid vaccine suppliers upends deliveries, the German federal government is drawing up plans to build up production within its borders, federal health minister Jens Spahn said at a weekly news conference, thereby confirming remarks made by future vaccine commissioner Christoph Krupp in a pre-published newspaper interview.
Expert Statement: Matthias Braun, Sanofi-Aventis Germany
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
Sirion and Sanofi in Gene Therapy Partnership
Germany’s Sirion Biotech has signed a license and collaboration agreement with major French pharma Sanofi on viral vector-based gene therapy. Financial terms of the agreement were not disclosed. The partners aim to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
Sanofi to Produce J&J Covid Vaccine in France
On the same day that Sanofi and GSK announced the start of a new Phase 2 study of their delayed adjuvanted recombinant protein-based Covid-19 vaccine candidate, Sanofi disclosed it had signed an agreement to manufacture 12 million doses of Johnson & Johnson’s single-dose adenovirus-based Covid vaccine.
Sanofi Buys UK Biotech Kymab
French pharma Sanofi is once again boosting its immunotherapy capabilities, this time with the acquisition of UK biotech Kymab. The company will make an upfront payment of about $1.1 billion plus up to $350 million upon Kymab achieving certain milestones.
Sanofi is Overall Winner of ISPE’s 2020 Facility of the Year Awards
The International Society for Pharmaceutical Engineering (ISPE) has announced Sanofi as the 2020 Facility of the Year Awards (FOYA) Overall Winner.
Sanofi Strengthens Immunology with Kiadis Buy
French pharma Sanofi is boosting once again its immunology portfolio with an agreement to buy Dutch biotech Kiadis for €308 million.
Sanofi Completes Principia Acquisition
French drugmaker Sanofi has completed its acquisition of US-based Principia Biopharma for $100 per share in cash. The takeover worth altogether $3.7 billion was sealed following expiration of the tender offer for all of Principia’s shares on Sept. 25.
Sanofi/GSK and Moderna Seal Vaccine Supply in Canada
Both the Sanofi/GlaxoSmithKline partnership and US vaccine producer Moderna this week announced new advance purchase agreements with Canada for their Covid-19 vaccine candidates.
Sanofi and GSK Ink EU Vaccine Deal
Sanofi and GSK have agreed a deal with the EU to supply up to 300 million doses of their recombinant protein-based Covd-19 vaccine pending regulatory approval, which is expected sometime in the first half of 2021.
Vaccine Makers Pledge Caution on Covid Rollout
With some potential Covid-19 vaccine makers suggesting they could have a candidate ready for approval and maybe even deployment this autumn, concerns are arising that a doubting public could shun inoculation.
EU Seals AZ Vaccine Deal, Makes Strides on Others
After months of uncertainty and anxious glances across the water as potential Covid-19 vaccine manufacturers made deal after deal with other political blocs, the EU over the past four weeks has made rapid strides toward securing supplies for its 27 member states.
Sanofi Boosts Autoimmune Offering with Principia Buy
Sanofi has agreed to buy US-based Principia Biopharma for $3.68 billion, strengthening its pipeline of treatments for autoimmune disorders. The deal gives the French drugmaker access to Principia’s bruton tyrosine kinase (BTK) inhibitors, which are showing promise in blocking or disrupting the signaling processes that cause inflammation and tissue destruction in autoimmune diseases.
Chemical Market Reporter
Sartorius AG
CONTINUUS Pharmaceuticals, Inc.
GlobalData
Ehrfeld Mikrotechnik GmbH
EuroAPI
SchüllerConsulting
Sanofi-Aventis Deutschland
Partex N.V.
Metro Atlanta Chamber
Berlin Partner für Wirtschaft und Technologie GmbH
Merck & Co
CHEManager International c/o Wiley-VCH GmbH
Sanofi S.A.
Infraserv GmbH & Co. Höchst KG
Thomson Reuters
Together for Sustanability (TFS)
Bayer AG
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd
GlaxoSmithKline (GSK) plc
EvaluatePharma